Title : Neurorive has entered the first phase of Alzheimer's cognitive impairment treatment in Korea.
Neurorive announced on the 27th that it has entered the first phase of clinical trials in Korea for "NR-0701", a treatment for Alzheimer's cognitive impairment.
It is explained that it is being developed by focusing on increasing the efficacy of Donepezil, a representative cognitive impairment drug, and reducing side effects.
NR-0701 is being developed using acetylcholine enzyme inhibitors and PDE inhibitors used in Donepezil and Viagra, respectively, a company official said. "We are trying to maximize the ability of neurons to deliver information while reducing the toxicity of Viagra-based drugs."
Researchers at Cleveland Hospital in the U.S. recently published a study showing that Viagra can prevent the onset of cognitive impairment by 69%.
"Donpezil is the most prescribed treatment for cognitive impairment in the world, and PDE5 inhibitors are showing potential in several preclinical and clinical trials," said Yang Dong-won and Shim Yong-soo, a team professor of neurology at Catholic University of Medicine.
Lee Seok-chan, CEO of Neurorive, said, "The number of patients with cognitive impairment in Korea is expected to surge from 840,000 last year to 3 million by 2050, so related treatments are needed."
Do-hee Lee reporter (tuxi0123@hankyung.com)
URL : https://news.naver.com/main/read.naver?mode=LSD&mid=sec&sid1=105&oid=015&aid=0004657765
留言